alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 31.2
 
 Certification:
 
 I, Richard K Brock, certify that:
 
 1.I have reviewed this quarterly report on Form 10-QSB of Semele Group Inc;

2.Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4.The registrants other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and


5.The registrants other certifying officers and I have disclosed, based on our most recent evaluation of internal controls over financial reporting, to the registrants auditors and the audit committee of registrants board of directors (or persons performing the equivalent functions):

a)all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal controls over financial reporting.

6.The registrants other certifying officers and I have indicated in this quarterly report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.
 
 
 /s/ Richard K Brock
 Richard K Brock
 Vice President and Chief Financial Officer
 May 14, 2004
================================================================================

EXHIBIT 32.2

                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CirTran  Corporation on Form 10-QSB/A
for the period ending June 30, 2006, as filed with the  Securities  and Exchange
Commission on the date hereof (the "Report"),  Richard Ferrone,  Chief Financial
Officer of the  Company,  certifies,  pursuant  to 18 U.S.C.  Section  1350,  as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)     The Report fully  complies  with the  requirements  of section  13(a) or
15(d) of the Securities Exchange Act of 1934; and

(2)     The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the Company.

August 24, 2006

                                              /s/ Richard Ferrone
                                              ----------------------------------
                                              Richard Ferrone
                                              Chief Financial Officer





















--------------------------------------------------------------------------------
Michigan Supreme Court Lansing, Michigan

Stephen J. Markman , Chief Justice Brian K. Zahra Bridget M. McCormack David F. Viviano Richard H. Bernstein Joan L. Larsen Kurtis T. Wilder, Justices

I, Larry S. Royster , Clerk of the Michigan Supreme Court, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court. August 23 , 2017 

# Order

Clerk August 23 , 2017

15 6 1 81 ( 6 2 )
PATRICIA T. ESCH, Personal Representative of the ESTATE OF STEPHEN STILES, Plaintiff

- Appellee , SC: 1561 81 v COA: 332 933 Kent CC: 16

- 00 0859

- NH NASIM YACOB, M

. D ., JIM MC FADDEN, R

. N

. , MINERVA BOOKER, R

. N

. , ESTHER WEST, R

. N

. , CLAIRE EVERSON, L

. P

. N

. , DORIS LEMMEN, L

. P

. N

. , CORIZON HEALTH , INC., Defendants

- Appellants, and DAVID SOVA, D

. O

. , and WEST MICHIGAN U RGENT CARE, INC., Defendants

- Appellees

.

_________________________________________ _

/ On order of the C hief Justice , the motion of plaintiff

- appellee to extend the time for filing her answer to the application for leave to appeal is GRANTED. The answer will be accepted as timely filed if submitted on or before September 26 , 2017

.
Support Block 

Basic Issue: Sep 26/2013 A600-0763

Page 1 of 1

APPENDIX 2 

The following data is required to manufacture the Support Block tool if necessary, 

for bushing removals.
§ 520.540a Dexamethasone powder. ( a ) *Specifications.* Each packet contains 10 milligrams (mg) of dexamethasone.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use in cattle and horses* — ( 1 ) *Amount.* Administer 5 to 10 mg per animal the first day then 5 mg per day as required by drench or by sprinkling on a small amount of feed.
( 2 ) *Indications for use.* As supportive therapy following parenteral steroid administration for management or inflammatory conditions such as acute arthritic lameness, and for various stress conditions where corticosteroids are required while the animal is being treated for a specific condition.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Do not use in horses intended for human consumption.
[79 FR 28819, May 20, 2014]
§ 530.23 Procedure for setting and announcing safe levels. ( a ) FDA may issue an order establishing a safe level for a residue of an extralabel use of an approved human drug or an approved animal drug. The agency will publish in the Federal Register a notice of the order. The notice will include: ( 1 ) A statement setting forth the agency's finding that there is a reasonable probability that extralabel use in animals of the human drug or animal drug may present a risk to the public health;
( 2 ) A statement of the basis for that finding; and
( 3 ) A request for public comments.
( b ) A current listing of those drugs for which a safe level for extralabel drug use in food-producing animals has been established, the specific safe levels, and the availability, if any, of a specific analytical method or methods for drug residue detection will be codified in § 530.40.